CRISPR gene editing could kill HIV. But is it a cure?
In a provocative first step toward an elusive end to a devastating disease that has claimed 40 million lives, three patients have received CRISPR gene-editing therapies in an effort to eradicate HIV from their bodies.
The results — whether the men are cured or not after the one-time intravenous infusions this year — have not yet been disclosed by the San Francisco biotech company that created the technology based on Nobel Prize-winning research by UC Berkeley’s Jennifer Doudna.
But the potential treatment, called EBT-101, is safe and caused no major side effects, Excision BioTherapeutics reported at a meeting in Brussels.
Six more men will be treated, perhaps some at UC San Francisco, with higher doses. Participating in the research program is potentially risky: Participants stop their protective anti-HIV drugs for 12 weeks after gene-editing treatment to see if the virus is gone. Data will be presented at a medical conference next year, according to the company.
“We are opening the door for how this new drug will work and what potential it has for people living with HIV,” said Dr. William Kennedy, Excision senior vice president of clinical development. “Ultimately, we see this as a fundamentally new approach.”